101 related articles for article (PubMed ID: 29906406)
1. The malignancy index in plasma samples as a prostate cancer biomarker.
Serafin AM; Chinhengo A; Fernandez P; Akudugu JM
Discov Med; 2018 May; 25(139):235-242. PubMed ID: 29906406
[TBL] [Abstract][Full Text] [Related]
2. The malignancy index is a robust predictor of prostate cancer.
Serafin AM; Chinhengo A; Akudugu JM
Discov Med; 2020; 29(158):181-189. PubMed ID: 33007193
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
4. Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients.
Pedersen AN; Brünner N; Høyer-Hansen G; Hamer P; Jarosz D; Larsen B; Nielsen HJ; Stephens RW
Clin Chem; 1999 Aug; 45(8 Pt 1):1206-13. PubMed ID: 10430786
[TBL] [Abstract][Full Text] [Related]
5. Influence of freeze-drying on the recovery of the tumour invasion markers uPA and PAI-1 from prostate cancer resections.
Serafin AM; Akudugu JM; Bohm L
Ann Clin Biochem; 2015 May; 52(Pt 3):387-94. PubMed ID: 25355777
[TBL] [Abstract][Full Text] [Related]
6. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
7. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
8. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
9. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
10. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
11. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
12. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M
Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
14. uPA and PAI-1 in rectal cancer--relationship to radiotherapy and clinical outcome.
Angenete E; Langenskiöld M; Palmgren I; Falk P; Oresland T; Ivarsson ML
J Surg Res; 2009 May; 153(1):46-53. PubMed ID: 18533186
[TBL] [Abstract][Full Text] [Related]
15. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
[TBL] [Abstract][Full Text] [Related]
16. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of urokinase plasminogen activator for prostatic carcinoma.
Lehmann K; Plas E; Gautschi K; Hauri D
Urol Int; 1994; 52(3):159-61. PubMed ID: 7515534
[TBL] [Abstract][Full Text] [Related]
18. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
19. Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine: Results of a prospective multi-center study at certified breast centers.
Jacobs VR; Augustin D; Wischnik A; Kiechle M; Hoess C; Steinkohl O; Rack B; Kapitza T; Krase P
Breast; 2016 Oct; 29():208-12. PubMed ID: 27344290
[TBL] [Abstract][Full Text] [Related]
20. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Hoffmann G; Pollow K; Weikel W; Strittmatter HJ; Bach J; Schaffrath M; Knapstein P; Melchert F; Pollow B
Clin Chem Lab Med; 1999 Jan; 37(1):47-54. PubMed ID: 10094378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
